[
  {
    "item_id": "press_corporate__medincell_20251221_1781cc",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder",
    "content": "FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I DisorderOctober 10, 2025October 10, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/10/MDC_UZEDY-BDI_EN_10102025_vf.pdf",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:05.839440",
    "language": "en",
    "content_hash": "sha256:9af83ff908da116aea79f158b3ebdf544ae2c357adfb5de082941c5913f41ffb",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 24
    },
    "normalized_at": "2025-12-21T13:36:35.677058Z",
    "normalized_content": {
      "summary": "The FDA has approved an expanded indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a treatment for adults living with Bipolar I Disorder. UZEDY is a long-acting injectable formulation of risperidone.",
      "entities": {
        "companies": [],
        "molecules": [
          "risperidone",
          "UZEDY"
        ],
        "technologies": [
          "Extended-Release Injectable"
        ],
        "trademarks": [
          "UZEDY®"
        ],
        "indications": [
          "Bipolar I Disorder"
        ]
      },
      "event_classification": {
        "primary_type": "regulatory",
        "confidence": 0.8
      },
      "lai_relevance_score": 10,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [
        "tech_lai_ecosystem"
      ],
      "domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.9,
          "confidence": "high",
          "reasoning": "The item discusses an FDA approval for an extended-release injectable formulation of risperidone, which is directly relevant to the long-acting injectable technology focus of this domain.",
          "matched_entities": {
            "companies": [],
            "molecules": [
              "risperidone",
              "UZEDY"
            ],
            "technologies": [
              "Extended-Release Injectable"
            ],
            "trademarks": [
              "UZEDY®"
            ]
          }
        }
      },
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 7,
      "bonuses": {
        "regulatory_event": 2.5,
        "regulatory_tech_combo": 1.0,
        "high_lai_relevance": 2.5
      },
      "penalties": {},
      "final_score": 11.7,
      "score_breakdown": {
        "base_score": 7,
        "domain_relevance_factor": 0.81,
        "recency_factor": 1.0,
        "weighted_base": 5.67,
        "total_bonus": 6.0,
        "total_penalty": 0,
        "raw_score": 11.67,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20251221_516562",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults",
    "content": "Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in AdultsDecember 9, 2025December 9, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:05.839440",
    "language": "en",
    "content_hash": "sha256:c2ed94aa0c2dfe5546577b2452e9dc35255e76491c079fb1906d579722fa5fd2",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 33
    },
    "normalized_at": "2025-12-21T13:36:11.833085Z",
    "normalized_content": {
      "summary": "Teva Pharmaceuticals has submitted a New Drug Application to the U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK), a once-monthly treatment for schizophrenia in adults developed in partnership with Medincell.",
      "entities": {
        "companies": [
          "Medincell",
          "Teva Pharmaceuticals"
        ],
        "molecules": [
          "Olanzapine Extended-Release Injectable Suspension",
          "TEV-'749",
          "mdc-TJK"
        ],
        "technologies": [
          "Extended-Release Injectable",
          "Once-Monthly"
        ],
        "trademarks": [],
        "indications": [
          "Schizophrenia"
        ]
      },
      "event_classification": {
        "primary_type": "regulatory",
        "confidence": 0.8
      },
      "lai_relevance_score": 10,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [
        "tech_lai_ecosystem"
      ],
      "domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.8,
          "confidence": "high",
          "reasoning": "The item discusses an extended-release injectable formulation for schizophrenia, which aligns with the domain's focus on long-acting injectable technologies.",
          "matched_entities": {
            "companies": [
              "Medincell",
              "Teva Pharmaceuticals"
            ],
            "molecules": [
              "Olanzapine Extended-Release Injectable Suspension"
            ],
            "technologies": [
              "Extended-Release Injectable",
              "Once-Monthly"
            ],
            "trademarks": []
          }
        }
      },
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 7,
      "bonuses": {
        "regulatory_event": 2.5,
        "regulatory_tech_combo": 1.0,
        "high_lai_relevance": 2.5
      },
      "penalties": {},
      "final_score": 11.2,
      "score_breakdown": {
        "base_score": 7,
        "domain_relevance_factor": 0.75,
        "recency_factor": 1.0,
        "weighted_base": 5.25,
        "total_bonus": 6.0,
        "total_penalty": 0,
        "raw_score": 11.25,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20251221_6f822c",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products",
    "content": "PRESSRELEASES10 December, 2025Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based productsThe agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.READ MORE6 November, 2025Nanexa publishes interim report for January-September 2025We have progresse",
    "url": "https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:00.316335",
    "language": "en",
    "content_hash": "sha256:a6f60bd2b0d446163f5bee10d1c134f77d3228b27e0b3e62cef64f33d4208a2d",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 71
    },
    "normalized_at": "2025-12-21T13:35:39.242115Z",
    "normalized_content": {
      "summary": "Nanexa and Moderna have entered into a license and option agreement for the development of up to five undisclosed compounds using Nanexa's PharmaShell® technology. Nanexa will receive an upfront payment and is eligible for milestone payments and royalties.",
      "entities": {
        "companies": [
          "Nanexa",
          "Moderna"
        ],
        "molecules": [],
        "technologies": [
          "PharmaShell®"
        ],
        "trademarks": [
          "PharmaShell®"
        ],
        "indications": []
      },
      "event_classification": {
        "primary_type": "partnership",
        "confidence": 0.8
      },
      "lai_relevance_score": 8,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [
        "tech_lai_ecosystem"
      ],
      "domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.7,
          "confidence": "high",
          "reasoning": "The item mentions PharmaShell, which is a technology for long-acting injectable formulations, matching the domain's focus.",
          "matched_entities": {
            "companies": [
              "Nanexa",
              "Moderna"
            ],
            "molecules": [],
            "technologies": [
              "PharmaShell®"
            ],
            "trademarks": [
              "PharmaShell®"
            ]
          }
        }
      },
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 8,
      "bonuses": {
        "partnership_event": 3.0,
        "high_lai_relevance": 2.5
      },
      "penalties": {},
      "final_score": 11.0,
      "score_breakdown": {
        "base_score": 8,
        "domain_relevance_factor": 0.69,
        "recency_factor": 1.0,
        "weighted_base": 5.52,
        "total_bonus": 5.5,
        "total_penalty": 0,
        "raw_score": 11.02,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20251221_6f822c",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products",
    "content": "10 December, 2025Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based productsThe agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.READ MORE",
    "url": "https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:00.316335",
    "language": "en",
    "content_hash": "sha256:d9b83fe6cb94dcaa8e1245f54fd2e589b6cf48151c4b60378d8012a5e5a20125",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 61
    },
    "normalized_at": "2025-12-21T13:35:44.428408Z",
    "normalized_content": {
      "summary": "Nanexa and Moderna have entered into a license and option agreement for the development of up to five undisclosed compounds using Nanexa's PharmaShell® technology. Nanexa will receive an upfront payment and is eligible for milestone payments and royalties.",
      "entities": {
        "companies": [
          "Nanexa",
          "Moderna"
        ],
        "molecules": [],
        "technologies": [
          "PharmaShell®"
        ],
        "trademarks": [
          "PharmaShell®"
        ],
        "indications": []
      },
      "event_classification": {
        "primary_type": "partnership",
        "confidence": 0.8
      },
      "lai_relevance_score": 8,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [
        "tech_lai_ecosystem"
      ],
      "domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.7,
          "confidence": "high",
          "reasoning": "The item mentions PharmaShell, which is a technology for developing long-acting injectable formulations, aligning with the domain's focus.",
          "matched_entities": {
            "companies": [
              "Nanexa",
              "Moderna"
            ],
            "molecules": [],
            "technologies": [
              "PharmaShell®"
            ],
            "trademarks": [
              "PharmaShell®"
            ]
          }
        }
      },
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 8,
      "bonuses": {
        "partnership_event": 3.0,
        "high_lai_relevance": 2.5
      },
      "penalties": {},
      "final_score": 11.0,
      "score_breakdown": {
        "base_score": 8,
        "domain_relevance_factor": 0.69,
        "recency_factor": 1.0,
        "weighted_base": 5.52,
        "total_bonus": 5.5,
        "total_penalty": 0,
        "raw_score": 11.02,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20251221_c147c4",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025",
    "content": "UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025November 5, 2025November 5, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:05.839440",
    "language": "en",
    "content_hash": "sha256:7f3a6a00314b234fd43355bd5206916bed56d46d3f812a774fb1cbb61c28ec28",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 22
    },
    "normalized_at": "2025-12-21T13:36:30.087626Z",
    "normalized_content": {
      "summary": "Teva's UZEDY® continues strong growth, and the company is preparing for a US NDA submission for its Olanzapine Long-Acting Injectable (LAI) in Q4 2025.",
      "entities": {
        "companies": [
          "Teva"
        ],
        "molecules": [
          "UZEDY®",
          "Olanzapine"
        ],
        "technologies": [
          "Long-Acting Injectable"
        ],
        "trademarks": [
          "UZEDY®"
        ],
        "indications": []
      },
      "event_classification": {
        "primary_type": "clinical_update",
        "confidence": 0.8
      },
      "lai_relevance_score": 10,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [
        "tech_lai_ecosystem"
      ],
      "domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.8,
          "confidence": "high",
          "reasoning": "The item mentions Teva's long-acting injectable (LAI) product Olanzapine LAI, which is directly relevant to the LAI technology focus of this domain.",
          "matched_entities": {
            "companies": [
              "Teva"
            ],
            "molecules": [
              "Olanzapine"
            ],
            "technologies": [
              "Long-Acting Injectable"
            ],
            "trademarks": []
          }
        }
      },
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 6,
      "bonuses": {
        "clinical_event": 2.0,
        "high_lai_relevance": 2.5
      },
      "penalties": {},
      "final_score": 9.0,
      "score_breakdown": {
        "base_score": 6,
        "domain_relevance_factor": 0.75,
        "recency_factor": 1.0,
        "weighted_base": 4.5,
        "total_bonus": 4.5,
        "total_penalty": 0,
        "raw_score": 9.0,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20251221_150759",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Awarded New Grant to Fight Malaria",
    "content": "Medincell Awarded New Grant to Fight MalariaNovember 24, 2025November 24, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:05.839440",
    "language": "en",
    "content_hash": "sha256:2077438074167cf84530cd63f435d4d32c7966446ec74b1d2d88da3c63b8e447",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 11
    },
    "normalized_at": "2025-12-21T13:36:16.253111Z",
    "normalized_content": {
      "summary": "Medincell, a biotech company, has been awarded a new grant to develop long-acting injectable formulations to fight malaria.",
      "entities": {
        "companies": [
          "Medincell"
        ],
        "molecules": [],
        "technologies": [
          "Long-Acting Injectable"
        ],
        "trademarks": [],
        "indications": [
          "Malaria"
        ]
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "lai_relevance_score": 9,
      "anti_lai_detected": false,
      "pure_player_context": true,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [
        "tech_lai_ecosystem"
      ],
      "domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.8,
          "confidence": "high",
          "reasoning": "The item mentions the development of a long-acting injectable formulation, which is directly relevant to the domain's technology focus.",
          "matched_entities": {
            "companies": [
              "Medincell"
            ],
            "molecules": [],
            "technologies": [
              "Long-Acting Injectable"
            ],
            "trademarks": []
          }
        }
      },
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {
        "pure_player_context": 2.0,
        "high_lai_relevance": 2.5
      },
      "penalties": {
        "low_relevance_event": -1.0
      },
      "final_score": 5.8,
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.75,
        "recency_factor": 1.0,
        "weighted_base": 2.25,
        "total_bonus": 4.5,
        "total_penalty": -1.0,
        "raw_score": 5.75,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__delsitech_20251221_e3d7ad",
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28",
    "content": "Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28Essi Nevo2025-08-15T11:33:54+02:00August 15th, 2025|Read More",
    "url": "https://www.delsitech.com/partnership-opportunities-in-drug-delivery-2025-boston-october-27-28/",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:11.914087",
    "language": "en",
    "content_hash": "sha256:9362998c5af4ef533152f4c2d2f7f2a5a831f17fb5c84d2e9918492eabf312d7",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 13
    },
    "normalized_at": "2025-12-21T13:36:42.788526Z",
    "normalized_content": {
      "summary": "The text is about an upcoming conference on partnership opportunities in drug delivery technologies, with a focus on long-acting injectable (LAI) technologies. No specific companies, drugs, or indications are mentioned.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [
          "Extended-Release Injectable",
          "Long-Acting Injectable",
          "Depot Injection",
          "Once-Monthly Injection",
          "Microspheres",
          "PLGA",
          "In-Situ Depot",
          "Hydrogel",
          "Subcutaneous Injection",
          "Intramuscular Injection"
        ],
        "trademarks": [
          "UZEDY",
          "PharmaShell",
          "SiliaShell",
          "BEPO",
          "Aristada",
          "Abilify Maintena"
        ],
        "indications": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "lai_relevance_score": 10,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [
        "tech_lai_ecosystem"
      ],
      "domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.9,
          "confidence": "high",
          "reasoning": "The item discusses technologies and trademarks related to long-acting injectable drug delivery, which aligns with the domain's focus.",
          "matched_entities": {
            "companies": [],
            "molecules": [],
            "technologies": [
              "Extended-Release Injectable",
              "Long-Acting Injectable",
              "Depot Injection",
              "Once-Monthly Injection",
              "Microspheres",
              "PLGA",
              "In-Situ Depot",
              "Hydrogel",
              "Subcutaneous Injection",
              "Intramuscular Injection"
            ],
            "trademarks": [
              "UZEDY",
              "PharmaShell",
              "SiliaShell",
              "BEPO",
              "Aristada",
              "Abilify Maintena"
            ]
          }
        }
      },
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {
        "high_lai_relevance": 2.5
      },
      "penalties": {
        "low_relevance_event": -1.0
      },
      "final_score": 3.1,
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.81,
        "recency_factor": 1.0,
        "weighted_base": 1.62,
        "total_bonus": 2.5,
        "total_penalty": -1.0,
        "raw_score": 3.12,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20251221_ec88d7",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "content": "6 November, 2025Nanexa publishes interim report for January-September 2025We have progressed with the optimization of our GLP-1 formulations, extended an existing commercial partnership, received approval for a PharmaShell patent application in Japan and submitted three new patent applications.READ MORE",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:00.316335",
    "language": "en",
    "content_hash": "sha256:0ae524c2c1742348fd5891a0d63556633a6fe131dc6d0a64705a3620d73771c9",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 39
    },
    "normalized_at": "2025-12-21T13:35:49.705208Z",
    "normalized_content": {
      "summary": "Nanexa published an interim report for January-September 2025, highlighting progress in optimizing GLP-1 formulations, extending a commercial partnership, receiving a patent approval in Japan, and submitting three new patent applications.",
      "entities": {
        "companies": [
          "Nanexa"
        ],
        "molecules": [
          "GLP-1"
        ],
        "technologies": [],
        "trademarks": [
          "PharmaShell"
        ],
        "indications": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "lai_relevance_score": 3,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [
        "tech_lai_ecosystem"
      ],
      "domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.6,
          "confidence": "medium",
          "reasoning": "The item mentions GLP-1 formulations, which could be related to long-acting injectable technologies, but there are no explicit technology details provided.",
          "matched_entities": {
            "companies": [],
            "molecules": [
              "GLP-1"
            ],
            "technologies": [],
            "trademarks": []
          }
        }
      },
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "medium_lai_score": -1.5,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.54,
        "recency_factor": 1.0,
        "weighted_base": 1.62,
        "total_bonus": 0,
        "total_penalty": -2.5,
        "raw_score": -0.88,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20251221_ec88d7",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "content": "6 November, 2025Nanexa publishes interim report for January-September 2025Download attachment",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:00.316335",
    "language": "en",
    "content_hash": "sha256:5e92a34fa02feb0c756160060d140bd43be564d228173af1a7475fc55abd2012",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 10
    },
    "normalized_at": "2025-12-21T13:35:53.718369Z",
    "normalized_content": {
      "summary": "Nanexa published its interim financial report for the period January-September 2025.",
      "entities": {
        "companies": [
          "Nanexa"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "lai_relevance_score": 0,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "low_lai_score": -3.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.15,
        "total_bonus": 0,
        "total_penalty": -4.0,
        "raw_score": -3.85,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20251221_e8d104",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Download attachment",
    "content": "Download attachment",
    "url": "https://storage.mfn.se/ab91ff14-4c8b-4c40-85a9-996052a19950/nanexa-interim-report-january-september-2025.pdf",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:00.316335",
    "language": "en",
    "content_hash": "sha256:3d03c0ba4af110790f2466800ad3cb177d90875ff5aca390550800cb8fb5b287",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 2
    },
    "normalized_at": "2025-12-21T13:35:57.531401Z",
    "normalized_content": {
      "summary": "The provided text does not contain any relevant content for analysis.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "lai_relevance_score": 0,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {},
      "penalties": {
        "low_lai_score": -3.0,
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.1,
        "total_bonus": 0,
        "total_penalty": -6.0,
        "raw_score": -5.9,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20251221_76ad60",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-June 2025",
    "content": "27 August, 2025Nanexa publishes interim report for January-June 2025Download attachment",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-june-2025/",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:00.316335",
    "language": "en",
    "content_hash": "sha256:5ebaa7e082a1cf6d1df5f67bacd000c99e99c281c9cc7c0d2499114067d696b3",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 10
    },
    "normalized_at": "2025-12-21T13:36:02.101094Z",
    "normalized_content": {
      "summary": "Nanexa published its interim financial report for the first half of 2025. No specific details about products, technologies or indications are provided.",
      "entities": {
        "companies": [
          "Nanexa"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "lai_relevance_score": 0,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "low_lai_score": -3.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.15,
        "total_bonus": 0,
        "total_penalty": -4.0,
        "raw_score": -3.85,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20251221_2b08cd",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)",
    "content": "Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)December 9, 2025December 9, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_HY-Results-EN_09122025-1.pdf",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:05.839440",
    "language": "en",
    "content_hash": "sha256:d31f0b2539d43d16674e54130adf76dadd16de4d64da01b46089ef7d05087f56",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 19
    },
    "normalized_at": "2025-12-21T13:36:06.251597Z",
    "normalized_content": {
      "summary": "Medincell published its consolidated half-year financial results for the period from April 1st, 2025 to September 30, 2025.",
      "entities": {
        "companies": [
          "Medincell"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "lai_relevance_score": 0,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "low_lai_score": -3.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.15,
        "total_bonus": 0,
        "total_penalty": -4.0,
        "raw_score": -3.85,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20251221_63c5d2",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth",
    "content": "Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital GrowthNovember 11, 2025November 11, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_G_KIM_10112025_EN_vf.pdf",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:05.839440",
    "language": "en",
    "content_hash": "sha256:0fd65830bac79a1367fb57ebdb608040c3d60da28c61faceaa909e7a158b29f2",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 23
    },
    "normalized_at": "2025-12-21T13:36:20.418044Z",
    "normalized_content": {
      "summary": "Medincell has appointed Dr Grace Kim as Chief Strategy Officer for U.S. Finance to advance the company's growth in the U.S. capital market.",
      "entities": {
        "companies": [
          "Medincell"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "lai_relevance_score": 2,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {
        "low_lai_score": -3.0
      },
      "final_score": 0,
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.25,
        "total_bonus": 0,
        "total_penalty": -3.0,
        "raw_score": -2.75,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20251221_846e38",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark",
    "content": "Medincell to Join MSCI World Small Cap Index, a Leading Global BenchmarkNovember 10, 2025November 10, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_MSCI-Small-Index_10112025_EN_vf.pdf",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:05.839440",
    "language": "en",
    "content_hash": "sha256:56a3453e4ee40153ae56677367b25aa29f62e6fdeeba03e4c9c8d2f2706a1923",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 16
    },
    "normalized_at": "2025-12-21T13:36:24.674494Z",
    "normalized_content": {
      "summary": "Medincell, a pharmaceutical company, will be included in the MSCI World Small Cap Index, a leading global benchmark.",
      "entities": {
        "companies": [
          "Medincell"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "lai_relevance_score": 0,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {
        "low_lai_score": -3.0
      },
      "final_score": 0,
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.25,
        "total_bonus": 0,
        "total_penalty": -3.0,
        "raw_score": -2.75,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__delsitech_20251221_ad0afc",
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "BIO International Convention 2025 Boston, June 16-19",
    "content": "BIO International Convention 2025 Boston, June 16-19Aleksi Leino2025-06-12T15:59:56+02:00June 12th, 2025|Read More",
    "url": "https://www.delsitech.com/bio-international-convention-2025-boston-june-16-19/",
    "published_at": "2025-12-21",
    "ingested_at": "2025-12-21T13:32:11.914087",
    "language": "en",
    "content_hash": "sha256:57720ff336bac6a3ca5237373c94baaa3eec122461772429e7c57553296abdcf",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 11
    },
    "normalized_at": "2025-12-21T13:36:46.759611Z",
    "normalized_content": {
      "summary": "This is an announcement for the BIO International Convention 2025 to be held in Boston from June 16-19, 2025. No specific details about companies, drugs, or technologies are provided.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "lai_relevance_score": 0,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "1.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {},
      "penalties": {
        "low_lai_score": -3.0,
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.1,
        "total_bonus": 0,
        "total_penalty": -6.0,
        "raw_score": -5.9,
        "scoring_mode": "balanced"
      }
    }
  }
]